Glenmark Launches Covid-19 Drug After Dcgi Nod

Glenmark Pharmaceuticals On Saturday Said It Has Launched Antiviral Drug Favipiravir, Under The Brand Name Fabiflu, For The Treatment Of Patients With Mild To Moderate Covid-19. The Mumbai-Based Drug Firm Had On Friday Received Manufacturing And Marketing Approval From The Drugs Controller General Of India (Dcgi).Fabiflu Is The First Oral Favipiravir-Approved Medication For The Treatment Of Covid-19, The Company Said In A Statement."This Approval Comes At A Time When Cases In India Are Spiralling Like Never Before, Putting A Tremendous Pressure On Our Healthcare System," Glenmark Pharmaceuticals Chairman And Managing Director Glenn Saldanha Said.The Company Hopes That The Availability Of An Effective Treatment Such As Fabiflu Will Considerably Help Assuage This Pressure, And Offer Patients In India A Much Needed And Timely Therapy Option, He Added.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!